Novel effect of topical Roquinimex and its combination with Clobetasol on an imiquimod-induced model of psoriasis in mice

Hasan, Abeer Mohammed; Gatea, Fouad Kadhim

doi:10.1007/s00210-024-02947-6

Cited by 1 publication

(7 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prototype of imiquimod-aggravated psoriasis in mice is more broadly utilized for experiments on molecular processes, antipsoriatic medication development, and percutaneous drug absorption. 70,75,126,127 In tandem with past investigations, an 8day administration of imiquimod to mouse dorsal skinfolds gave rise to psoriasiform plaques characterized by redness, desquamation, and acanthosis, along with upregulated expression of pro-inflammatory, angiogenic, and oxidative parameters. 31,32,38,72 It was documented that the skin lesions in the imiquimodapplied murine model, involving redness, acanthosis/thickening, scaling/flaking, cutaneous histology modifications (Munro's abscesses, hyperkeratosis, parakeratosis), and sproutingangiogenesis, alongside an inflammatory penetration made up of T lymphocytes, mast cells, neutrophils, and dendritic cell populations, were remarkably similar to those observed in human psoriasis vulgaris.…”

Section: ■ Discussionmentioning

confidence: 79%

“…White-gray peelings built up as a consequence of keratinocyte improper differentiation. 31,32,70 Calcipotriol is a standard first-choice topical medication intended for managing plaque-type psoriasis. It is a synthetic analogue of calcitriol, the active component of vitamin D, that may be selectively bound to vitamin D receptors and have a gene transcriptional impact, resulting in reduced aberrant growth and division of keratinocytes.…”

Section: ■ Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

“…An assessment score of 0 suggests that there is no visible lesion, 1 suggests that the epidermis is only slightly pink, 2 suggests that it appears pink, 3 suggests that it appears red, and 4 suggests that it is dark red. The sum of total scoring for erythema, scaling, and thickness was employed to assess the intensity of cumulative PASI on a scale from 0 to 12. − …”

Section: Methodsmentioning

confidence: 99%

“…During the 16-day experiment, individual measurements of epidermal thickness, erythema, and silvery-white scaling of the exposed dorsal skinfolds were recorded every day to compute the psoriasis area and severity index (PASI), which provides an estimation of the severity of psoriatic inflammation. 38,69,70 Erythema, scaling flakes, and epidermal thickness/induration were principally assigned scores that ranged from 0 to 4, based on the preceding parameters: 0 refers to none, 1 refers to mild, 2 denotes moderate, 3 refers to very marked, and 4 refers to very marked. A red-taint scoring method has been utilized to determine the degree of erythema.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Mitigative Effects of Topical Norfloxacin on an Imiquimod-Induced Murine Model of Psoriasis

Ridha-Salman,

Shihab,

Hasan

et al. 2024

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

Psoriasis is a chronic, inflammatory dermatosis characterized by thickened, reddened, and scaly skin lesions. Norfloxacin is a fluoroquinolone antibiotic with enhanced antioxidant, anti-inflammatory, and immunomodulatory bioactivities. The aim of this study was to figure out the possible impact of topical norfloxacin on an imiquimod-induced model of psoriasis in mice. Thirty albino-type mice were split into five distinct groups of six animals each. The control group included healthy mice that had not received any treatment. The induction group was given the vehicle 2 h after the topical imiquimod, once daily for 8 days. Two hours after receiving topical imiquimod, the treatment groups including calcipotriol, norfloxacin 2.5%, and norfloxacin 5% were given topical ointments containing calcipotriol 0.005%, norfloxacin 2.5%, and norfloxacin 5%, for 8 days. Topical norfloxacin ointment significantly reduced the severity of imiquimod-exacerbated psoriatic lesions including erythema, shiny-white scaling, and acanthosis and fixed histological abnormalities. Furthermore, imiquimod-subjected mice treated with a higher concentration of norfloxacin ointment exhibited dramatically lower skin levels of inflammation-related biomarkers like IFN-γ, TNF-α, IL-6, IL-17A, IL-23, and TGF-β but higher levels of IL-10. They also demonstrated a notable decrease in angiogenesis parameters such as VEGF and IL-8, a substantial reduction in oxidative indicators like MDA and MPO, and a considerable rise in antioxidant enzymes like SOD and CAT. This study offers novel evidence that norfloxacin may assist in controlling inflammatory dermatoses like psoriasis by minimizing the severity of psoriatic plaques, correcting histological alterations, and diminishing the production of inflammatory, oxidative, and angiogenetic parameters.

show abstract